Selected ongoing studies with elotuzumab- and CD38-targeting antibody-containing regimens in newly diagnosed MM
| Study . | Phase . | Setting . | Treatment . |
|---|---|---|---|
| NCT01335399 (ELOQUENT-1) | 3 | Nontransplant eligible | Lenaldiomide-dexamethasone vs lenalidomide-dexamethasone with elotuzumab |
| NCT02420860 | 2 | Transplant eligible | Elotuzumab with lenalidomide as maintenance after auto-SCT |
| NCT02495922 | 3 | Transplant eligible | Four study arms A1: RVD induction–auto-SCT–RVD consolidation–lenalidomide and dexamethasone maintenance A2: RVD induction–auto-SCT–RVD with elotuzumab consolidation–lenalidomide and dexamethasone with elotuzumab maintenance B1: RVD with elotuzumab induction–auto-SCT–RVD consolidation–lenalidomide and dexamethasone maintenance B2: RVD with elotuzumab induction–auto-SCT–RVD with elotuzumab consolidation–lenalidomide and dexamethasone with elotuzumab maintenance |
| NCT02375555 | 2a | Transplant eligible | Elotuzumab plus bortezomib, lenalidomide and dexamethasone (patients have option to undergo auto-SCT) |
| NCT01668719 | 1/2 | High-risk MM and age ≥18 years | Phase 1: Elotuzumab plus bortezomib, lenalidomide, and dexamethasone Phase 2: bortezomib-lenalidomide-dexamethasone vs bortezomib-lenalidomide-dexamethasone with elotuzumab |
| NCT01998971 | 1b | Irrespective of transplant eligibility for VD and VTD, and transplant ineligible for VMP | Daratumumab combined with VD, VTD, or VMP |
| NCT02252172 (Maia) | 3 | Nontransplant eligible | Lenalidomide-dexamethasone vs lenalidomide-dexamethasone plus daratumumab |
| NCT02195479 (Alcyone) | 3 | Nontransplant eligible | VMP vs VMP with daratumumab |
| NCT02541383 (Cassiopeia; IFM 2015-01; HOVON 131) | 3 | Transplant eligible | Randomization 1: VTD induction therapy–high-dose melphalan plus autologous stem cell rescue–VTD consolidation vs VTD with daratumumab induction therapy–high-dose melphalan plus autologous stem cell rescue–VTD with daratumumab consolidation Randomization 2: daratumumab as single agent in maintenance vs observation only |
| NCT02513186 | 1 | Nontransplant eligible | Isatuximab in combination with CyBorD |
| Study . | Phase . | Setting . | Treatment . |
|---|---|---|---|
| NCT01335399 (ELOQUENT-1) | 3 | Nontransplant eligible | Lenaldiomide-dexamethasone vs lenalidomide-dexamethasone with elotuzumab |
| NCT02420860 | 2 | Transplant eligible | Elotuzumab with lenalidomide as maintenance after auto-SCT |
| NCT02495922 | 3 | Transplant eligible | Four study arms A1: RVD induction–auto-SCT–RVD consolidation–lenalidomide and dexamethasone maintenance A2: RVD induction–auto-SCT–RVD with elotuzumab consolidation–lenalidomide and dexamethasone with elotuzumab maintenance B1: RVD with elotuzumab induction–auto-SCT–RVD consolidation–lenalidomide and dexamethasone maintenance B2: RVD with elotuzumab induction–auto-SCT–RVD with elotuzumab consolidation–lenalidomide and dexamethasone with elotuzumab maintenance |
| NCT02375555 | 2a | Transplant eligible | Elotuzumab plus bortezomib, lenalidomide and dexamethasone (patients have option to undergo auto-SCT) |
| NCT01668719 | 1/2 | High-risk MM and age ≥18 years | Phase 1: Elotuzumab plus bortezomib, lenalidomide, and dexamethasone Phase 2: bortezomib-lenalidomide-dexamethasone vs bortezomib-lenalidomide-dexamethasone with elotuzumab |
| NCT01998971 | 1b | Irrespective of transplant eligibility for VD and VTD, and transplant ineligible for VMP | Daratumumab combined with VD, VTD, or VMP |
| NCT02252172 (Maia) | 3 | Nontransplant eligible | Lenalidomide-dexamethasone vs lenalidomide-dexamethasone plus daratumumab |
| NCT02195479 (Alcyone) | 3 | Nontransplant eligible | VMP vs VMP with daratumumab |
| NCT02541383 (Cassiopeia; IFM 2015-01; HOVON 131) | 3 | Transplant eligible | Randomization 1: VTD induction therapy–high-dose melphalan plus autologous stem cell rescue–VTD consolidation vs VTD with daratumumab induction therapy–high-dose melphalan plus autologous stem cell rescue–VTD with daratumumab consolidation Randomization 2: daratumumab as single agent in maintenance vs observation only |
| NCT02513186 | 1 | Nontransplant eligible | Isatuximab in combination with CyBorD |
auto-SCT, autologous stem cell transplantation; RVD, lenalidomide, bortezomib, and dexamethasone; VD, bortezomib-dexamethasone; VMP, bortezomib, melphalan and prednisone; CyBorD, cyclophosphamide, bortezomib, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone.